SCHEMBL26969658

SCHEMBL26969658

COC(OC)[C@@H]1CCN(c2ccc(C(=O)O)c(C=O)c2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
NOTUM Q6P988 7/20 0.35
KCNH2 Q12809 2/20 0.34
USP2 O75604 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
USP30 Q70CQ3 2/20 0.33
POLB P06746 2/20 0.33
NSD2 O96028 1/20 0.33
PKM P14618 1/20 0.33
APEX1 P27695 1/20 0.33
CASP3 P42574 1/20 0.33
RECQL P46063 1/20 0.33
CASP6 P55212 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
IP6K1 Q92551 1/20 0.33
MAPT P10636 1/20 0.32
DPP4 P27487 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27123984 1.00 ALDH1A1 (0.36) ALDH1A1NOTUMKCNH2USP2MTNR1A
SCHEMBL27345261 0.90 ALDH1A1 (0.36) ALDH1A1NOTUMMTNR1AMTNR1BUSP30
SCHEMBL26969619 0.90 ALDH1A1 (0.36) ALDH1A1NOTUMMTNR1AMTNR1BUSP30
SCHEMBL24320368 0.83 ALDH1A1 (0.40) ALDH1A1POLBMAPTNPC1RAB9A
SCHEMBL27123954 0.81 CHRM4 (0.42) NOTUMUSP30
SCHEMBL26969638 0.81 CHRM4 (0.42) NOTUMUSP30
SCHEMBL24319289 0.80 ALDH1A1 (0.36) ALDH1A1POLBMAPTNPC1RAB9A
SCHEMBL25370050 0.76 PTPN1 (0.41) NOTUMUSP30IP6K1
SCHEMBL24778697 0.76 HIF1A (0.41) ALDH1A1NOTUMUSP2USP30IP6K1
SCHEMBL31315432 0.76 HIF1A (0.46) ALDH1A1USP2L3MBTL1MAPTDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416240-A1 KAT6 TARGETING COMPOUNDS PRELUDE THERAPEUTICS, INCORPORATED 2023-12-28 US disclosed
WO-2023245150-A1 KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY PRELUDE THERAPEUTICS INCORPORATED (US) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416240-A1 KAT6 TARGETING COMPOUNDS KAT6A, KAT6B, KAT2A ALDH1A1 3656/4885NOTUM 3085/4885KCNH2 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.